Key points are not available for this paper at this time.
Shareable abstract Triple combinations of CFTR modulators have revolutionized the care of people with cystic fibrosis (CF). Initially developed for the F508del variant, these drugs are effective in many other CFTR variants, making them suitable for most, but not all, pwCF.
Burgel et al. (Thu,) studied this question.